Our partner, uniQure, is planning on starting a clinical trial for Huntington's later this year.
https://huntingtonsdiseasenews.com/2018/01/18/uniqure-plans-human-trial-gene-therapy-amt-130/
As the design of their drug is not pure ddRNAi and as our core patent expires in April, it is not clear if the start of the trial will trigger a milestone payment or not.